KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GSK) FCF Margin (2016 - 2026)

Gsk has reported FCF Margin over the past 18 years, most recently at 20.59% for Q1 2026.

  • For Q1 2026, FCF Margin rose 52.0% year-over-year to 20.59%; the TTM value through Mar 2026 reached 28.37%, up 698.0%, while the annual FY2025 figure was 19.57%, 314.0% up from the prior year.
  • FCF Margin for Q1 2026 was 20.59% at Gsk, down from 33.08% in the prior quarter.
  • Over five years, FCF Margin peaked at 41.0% in Q1 2022 and troughed at 2.18% in Q4 2022.
  • A 5-year average of 22.12% and a median of 21.46% in 2023 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: plummeted -3936bps in 2022 and later soared 3410bps in 2023.
  • Year by year, FCF Margin stood at 2.18% in 2022, then soared by 1563bps to 31.92% in 2023, then tumbled by -41bps to 18.84% in 2024, then skyrocketed by 76bps to 33.08% in 2025, then plummeted by -38bps to 20.59% in 2026.
  • Business Quant data shows FCF Margin for GSK at 20.59% in Q1 2026, 33.08% in Q4 2025, and 29.64% in Q3 2025.